Deletions and ampli®cations are frequent alterations of the short arm of chromosome 8 associated with various types of cancers, including breast cancers. This indicates the likely presence of tumor suppressor genes and oncogenes. In the present study, we have used the expressed sequence tag (EST) map of 8p11-21 to assemble a set of available cDNAs representing genes from this region. DNA arrays were prepared for expression analysis and search for genes potentially involved in breast cancer. Underexpresion in tumoral breast cells (versus normal breast) was observed for 15 transcripts. Among these, the Frizzled-related gene FRP1/FRZB, was turned o in 78% of breast carcinomas, suggesting that the lack of its product may be associated with malignant transformation. Overexpression in tumoral breast cells was observed for 13 genes. The FGFR1 gene, that encodes a tyrosine kinase receptor for members of the ®broblast growth factor family, was identi®ed as a good candidate for one ampli®cation unit. Taken together, our results demonstrate that such a strategy can rapidly identify genes with an altered pattern of expression and provide candidate genes for malignancies.
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The development and progression of cancer are accompanied by complex changes in patterns of gene expression (Vogelstein and Kinzler, 1993; Weinberg, 1995) . Methods have recently been developed to detect and quantify dierential gene expression on a large scale using cDNA arrays or DNA chips (see for review Jordan, 1998) . These novel techniques have taken advantage of large-scale expressed sequence tags (ESTs) sequencing projects (Adams et al., 1991 (Adams et al., , 1995 Houlgatte et al., 1995; Williamson et al., 1995; Hillier, 1996; Miller et al., 1997) , and have been used in a number of studies, including cancer (Kononen et al., 1998; Theillet, 1998) .
We used a cDNA array strategy to study the dierential expression of a set of genes located in the p11-21 region of the short arm of chromosome 8. Multiple and complex genetic alterations of this region are deletions found in various types of malignant tumors (see Leach et al., 1996 , for review), amplification in breast cancer (Theillet et al., 1993; Dib et al., 1995; AdeÂ laõÈ de et al., 1998) , and rearrangements in hematopoietic malignancies and references therein) indicating the likely presence of several tumor suppressor genes and oncogenes. In breast cancer, both deletions in dierent subregions as assessed by loss of heterozygosity analysis (Kerangueven et al., 1995; Yaremko et al., 1996; AdeÂ laõÈ de et al., 1998; Anbazhagan et al., 1998) and ampli®cation are found in the 8p11-21 region.
We selected, by consulting the EST-based gene map of chromosome 8 (Schuler et al., 1996) , a set of 114 transcripts corresponding to genes located in the 23 cM interval between GeÂ neÂ thon markers D8S560 and D8S519 (42 ± 65 cM interval from 8pter), as indicated by the Human Transcript Map database from the National Center for Biotechnology Information (http:// www . ncbi . nlm . nih . gov/cgi -bin/SCIENCE96/msrch2? CHR=8). All clones were obtained from the IMAGE (Integrated Molecular Analysis of Genomes and their Expression) collection at UK (Hinxton) or at German (RZPD, Berlin-Charlottenburg) Human Genome Project Resource Centres. Two cDNA clones that correspond to FGFR1 and PLAT (cDNA clones yj74c05 and yl34d11, respectively) as well as an unidenti®ed transcript (clone 7.5) we previously cloned (AdeÂ laõÈ de et al., 1998) were included in the set.
For dierential gene expression studies, the cDNA clones were arrayed on ®lters and tested by hybridization with complex probes (Bernard et al., 1996) from total RNAs from normal and tumoral tissues. Detection and quantitative analysis of hybridization pattern and intensities of arrayed clones were done following a scan in a Fujix Bas 1500 system (Fuji, Tokyo, Japan) by using Bioimagè HDG' software (BioImage, Ann Arbor, MI) running on an Unix workstation . Data reports were exported into a microcomputer and analysed using Excel software (Microsoft). The array-based expression results were normalized to control variations in labeling, hybridization conditions, and ®lter exposure of dierent complex probes by using b-Actin as a control (Bernard et al., 1996; Rocha et al., 1997 ; for details on experimental procedures and data handling, see our web site: http:// olan.marseille.inserm.fr/publications.html).
The reproducibility of the experiment was ®rst tested by sequential hybridization of two dierent RNA preparations from the same cell to the same ®lter. The pattern of hybridization intensities was identical for the two experiments (data not shown). The reproducibility of measurement was next examined by comparing the values obtained with two arrayed ®lters hybridized with two independent (experiments 1 and 2, Figure 1a ) cDNA complex probes made from the same RNA sample from mammary carcinoma MDA-MB-134 cell line. In the diagram, the signal intensities of cDNAs for one experiment plotted against those obtained for the other experiment show little dispersion around the diagonal, indicating a constant ratio of intensities. The ratios of intensities between the duplicate ®lters were within a factor of 3, a threshold value we selected for subsequent analyses.
Comparative expression analysis of MDA-MB-134 cells derived from ductal mammary carcinoma versus normal breast tissue identi®ed cDNAs that showed dierences in intensity ratios of 53-fold ( Figure 1b) . The cDNAs that correspond to FGFR1 and PLAT displayed the expected patterns in the MDA-MB-134 cells, overexpression and underexpression, respectively, as reported in previous works (Theillet et al., 1993; Dib et al., 1995) . In addition, comparison of gene expression was made for several 8p12 loci between MDA-MB-134 and HBL-100 ± a cell line derived from the immortalization of normal epithelial mammary cells ± (Figure 1c) , and between breast carcinoma tumor 4885 whose DNA is ampli®ed (without concomitant overexpression of FGFR1) ± and normal breast (Figure 1d ). In MDA-MB-134 and 4885, two classes of transcripts were identi®ed: underexpressed transcripts such as FRP1 and HGL genes (cDNA clones yl57a10 and yj87c03, respectively), and overexpressed transcripts such as FGFR1 in MDA-MB-134 and PLAT in 4885 human mammary tumor.
Among the 114 cDNAs, 57 were unambiguously assigned to a precise position on the high resolution physical and transcriptional map we constructed. Expression of these 57 genes in either normal (breast) or pseudo-normal breast tissue (HBL-100 cell line), as well as in another normal tissue, i.e., prostate, was extensively studied. In Figure 2a , hybridization signal intensities are represented using a grey color ladder indicating the dierent mRNA amounts in the probes. Fourteen per cent of the clones were either not or barely expressed in normal breast tissue. Forty four per cent of cDNAs had quite similar expression levels in normal breast and prostate tissues. Twenty-two per cent of cDNAs were signi®cantly more expressed in breast than in prostate. For most cDNAs (72%), expression levels were enhanced in HBL-100 compared to normal breast. These dierences could be explained by a higher physiological activity in established cell lines than in their primary counterpart. Thus, to avoid a bias in our data, subsequent analyses of dierential gene expression were done either for tumoral versus normal cell lines or for primary breast tumors versus normal breast.
Dierential gene expression analysis between normal and tumoral breast cells is shown in Figure 2c . Comprehensive results are expressed as hybridization intensity ratios between either each breast carcinoma cell line (four tested) and HBL-100 or each breast tumor (®ve tested) and normal breast. They represent the modulation of gene expression in tumor samples compared to normal tissues. Twenty-eight clones (49%) showed a dierential expression pattern in at least one carcinoma cell line and one tumor. The two classes of transcripts de®ned above, i.e., overexpressed and underexpressed transcripts, were detected. Fifteen genes displayed underexpression. Of them, 12 are located in subregions of deletion (Figure 2b ). In particular, expression of cDNA yl57a10 corresponding to the FRP1/FRZB gene was undetectable in all tumor samples (Figure 2c ). In contrast, 13 genes were overexpressed in tumor samples. They are all but one located between the HGL and PLAT genes (Figure 2b ), a region that is ampli®ed in breast tumors.
To con®rm these results, Northern blots containing RNAs from breast cell lines and normal breast tissue were probed with 25 cDNA clones corresponding to either known or novel genes. Representative results are Figure 2 Comparative analysis of cDNA expression (breast carcinomas versus normal breast and prostate cells). (a) The quanti®cation of the hybridization signals with cDNA probes from breast and prostate tissues allowed to assign each cDNA clone to a class of intensity (from the lowest level, level 1, to the highest one, level 7). cDNA clones are listed above according to the integrated map. (b) A portion of the genetic and physical 8p11-21 map is represented (not to scale); selected microsatellite markers or genes are listed in physical order from telomere (tel) to centromere (cen) and the relative distances between some of the GeÂ neÂ thon markers are shown in cM (Dib et al., 1996) . Dierent subregions of deletion as assessed by loss of heterozygosity analyses (LOH I-V) (AdeÂ laõÈ de et al., 1998, and data not shown) or with ampli®cation in breast cancer are shown. The putative region of localization of a third breast cancer susceptibility gene (Imbert et al., 1996; Seitz et al., 1997) shown in Figure 3a : overexpression of cDNA yv43f01 in MDA-MB-134, constant expression of cDNA yu79f08 in the three tissues, and loss of expression of cDNA yl57a10 in MDA-MB-134. For each transcript, a good correlation between expression measured by Northern blot hybridization and that measured by array hybridization was obtained (diagrams from Figure 3b and c, respectively), thus con®rming the results shown in Figure 2c .
Among the underexpressed genes, we identi®ed at least three putative tumor suppressor genes. EXTL3 (clone yy17e02), the third EXT-like gene (Van Hul et al., 1998) belongs to the family of genes involved in hereditary multiple exostoses (EXT) that may represent a class of tumor suppressors (McCormick et al., 1998) . Our data show that this gene is underexpressed in three sporadic breast tumors compared to normal tissue (Figure 2c ). The localization of this gene in the chromosomal interval thought to contain a breast susceptibility gene (Imbert et al., 1996; Seitz et al., 1997) , and its putative tumor suppressor function, make it a possible candidate for the 8p12-21 familial breast cancer gene. cDNA yj87c03, encoding Heregulin (HGL), also called Neu dierentiation factor or Neuregulin 1 (Holmes et al., 1992) is underexpressed in seven out of the nine carcinoma samples (Figure 2c ). Recent studies showed that HGL can arrest growth and induce dierentiation in prostate (Lyne et al., 1997) and breast cancer (Bacus et al., 1996) cells, suggesting that it may under certain circumstances play a role in tumor suppression.
cDNA yl57a10 encodes a Frizbee-like protein (FRZB: Zorn, 1997) , called Frizzled-related protein-1 (FRP1: Finch et al., 1997; Rattner et al., 1997) or Secreted apoptosis related protein-2 (SARP2: Melkonyan et al., 1997) . It belongs to a family of proteins that are secreted forms of the WNT receptors Frizzled. These proteins contain a cysteine-rich domain similar to that of Frizzled, but no transmembrane segments. They may bind to WNTs in solution and thereby change the activity of these factors. Wnt genes were ®rst identi®ed as mammary oncogenes, then as important developmental genes, and numerous WNT family members are expressed in normal and malignant mammary tissues (Nusse and Varmus, 1992; Dale et al., 1996) . To examine FRP1 involvement in breast tumorigenesis, we checked its expression by Northern blot analysis in a panel of human breast tissues and cell lines with dierent tumorigenic potentials (Figure 4 , rows 1 ± 4). FRP1 was detectable as a 4.4 kb transcript in normal breast and in the HBL-100 and MDA-MB-157 cell lines (the latter is derived from medullary carcinoma cells). In contrast, there was no detectable FRP1 transcript in MDA-MB-134 cells. Ninety breast carcinomas (83 ductal, six lobular, and one medullar) and 16 benign tumors were next examined for FRP1 expression and representative results are shown in Figure 4 (rows 5 ± 12 and 14 ± 17, respectively). Levels of FRP1 transcripts were downregulated in the majority of malignant tumors and undetectable by Northern blot in 78% of them. In contrast, only 19% (three out of 16 cases) of the benign tumors showed a lower level of FRP1 transcripts than that detected in normal breast. Our expression analysis in normal, nonmalignant and malignant breast samples demonstrated that FRP1 is expressed in normal breast and benign breast tumors. In contrast, it is drastically repressed in the majority of breast carcinomas. Interestingly, FRP1/ SARP2 protein has pro-apoptotic activity (Melkonyan et al., 1997) , and is thought to function as an inhibitor of WNT activity (Finch et al., 1997; Wang et al., 1997) . We localized the cDNA clone yl57a10 corresponding to FRP1/FRZB in the centromeric region of chromosome 8p (p11-12) between microsatellite markers D8S532 and D8S268, in a subregion of loss of heterozygosity, LOH V, in breast cancer (Figure 2b ). Thus it might be inactivated by deletion of genomic material. In agreement with recent works showing upregulation of FRP1 associated with apoptosis and its downregulation in breast tumors (Melkonyan et al., 1997; Zhou et al., 1998) , our results demonstrate the loss of expression of FRP1/FRZB in breast carcinomas and strongly suggest that it may act as tumor suppressor gene and that its inactivation can contribute to breast malignancy. Inappropriate activation of the WNT pathway appears to play a major role in human cancers. Several components that control this signaling cascade, such as APC, b-Catenin or CBP, can be altered, leading to abnormal proliferation (Pennisi, 1998; He et al., 1998) . We propose here that another checkpoint of this pathway may be de®cient in breast cancer, since one of the molecules that regulate the initial stimulation of the pathway may be the target of inactivation mechanisms. This adds strength to the mounting evidence that disruption of the WNT pathway controls could be essential to cancer cell proliferation and that this damage may happen at many dierent levels.
8p11-12 genes are ampli®ed in approximately 10 ± 15% of human breast carcinomas (Theillet et al., 1993; Dib et al., 1995; AdeÂ laõÈ de et al., 1998) . However, the key gene of the 8p12 amplicon is not precisely known yet. Gene ampli®cation was examined by sequential hybridizations of Southern blots containing DNA from a series of 659 breast carcinomas with probes corresponding to each of the 8p11-12 cDNAs. The results are summarized in Figure 5 . Of the 72 tumors (11%) with ampli®cation at 8p11-12, 64 were ampli®ed for markers localized within the genomic interval between cDNA yv43f01 and FGFR1 (approximately 10%), 61-54 (9 ± 8%) between cDNA yc89c10 and GFK1, and 42-41 (6%) from cDNA zd33e11 to the PLAT gene (see the respective cDNA and marker positions on Figure 2b and c). The overall results de®ne two discrete amplicons at 8p11-12, nearby the FGFR1 and PLAT genes, respectively. To determine whether the ampli®ed loci were associated with altered mRNA levels in breast cancers, Northern blot analyses were done on malignant breast cell lines and 132 unselected tumor samples. The same cDNA probes were used as probes. Interestingly, except for FGFR1 (15% of cases), none of the transcripts was overexpressed as the result of the ampli®cation of the gene. Thus, FGFR1, one of the four genes encoding tyrosine kinase receptors for ®broblast growth factors (reviewed in Johnson and Williams, 1993) , remains the best candidate for the main 8p11-12 ampli®cation unit.
The approach we describe appears useful to rapidly identify novel sequences in a region of ampli®cation. The present ®nding of two distinct ampli®cation sites at 8p11-12, including the previously known FGFR1 amplicon, resembles the complex ampli®cation patterns (see review in Schwab, 1998) reported for the 11q13 (Gaudray et al., 1992 ), 17q22-24 (BaÈ rlund et al., 1997 , and 20q12-13 regions in breast cancer. Based on comparative genomic hybridization, Courjal et al. (1997) described patterns of ampli®cation Figure 4 RNA blot analysis of FRP1/FRZB on normal breast, non-malignant (HBL-100) and malignant mammary carcinoma cell lines, eight malignant breast carcinomas, and four benign tumor samples. 10 mg of each sample were sequentially hybridized with 32 P-labeled human FRP1 probe and human b-Actin cDNA probe according to Church and Guilbert (1984) . Hybridization patterns were scanned in a Fujix Bas 1500 system (see details of the method on our web site: http://olan.marseille.inserm.fr/ publications.html). The respective transcript size is indicated on the left at 8p11-12 in favor of the existence of two cores, one de®ned by FGFR1 and the second in the vicinity of the anonymous marker GFK1 we generated in a previous work . This 8p structure could be coordinated by selections involving several genetic determinants (Courjal et al., 1997) . However, the fact that in our study, FGFR1 is the only gene that was both ampli®ed and overexpressed in tumors (except in very few tumors such as 4885), suggests that FGFR1 is a main contributor to the biological behavior of breast tumors with ampli®cation of the 8p11-12 region. The oncogenic role of FGFR1 has been recently demonstrated in human cancers: it is activated in translocations associated with a stem-cell myeloproliferative disorder Popovici et al., , 1999 Xiao et al., 1998) . Interestingly, FGFR1 activation through either rearrangement or amplification is reminiscent of the activation of 11q13 cyclin gene CCND1 (Zukerberg et al., 1995) .
The elucidation of speci®c pathogenetic contributions of these candidate genes should provide insight in the developnment and maintenance of the malignant phenotype. The dierential expression analysis of transcripts in normal and tumor breast tissues showed the utility of the array method to analyse complex diseases by their pattern of gene expression in a speci®c and well-characterized region of the genome. Our ®ndings show that such a strategy can easily identify genes with an altered pattern of expression. 
